Concepedia

The Association of <i>ERBB2</i>-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor–Positive, <i>ERBB2</i>-Negative Metastatic Breast Cancer

Kelvin K H Bao, Leone Sutanto, Shirley S. W. Tse, Ka Man Cheung, Jeffrey Chan

JAMA Network Open · 2021 · 53 citations · 3 references

DOIFull text

Open access

Concepts

Abstract

This cohort study investigates the association between low levels of ERBB2 expression and progression-free survival among patients with HR+/ERBB2− metastatic breast cancer treated with CDK4/6 inhibitors.

References

3

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

Shanu Modi, Haeseong Park, Rashmi K. Murthy et al. · Journal of Clinical Oncology · 2020 · 817 citations · Full text

, , +17

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

Sara M. Tolaney, Andrew Wardley, Stefania Zambelli et al. · The Lancet Oncology · 2020 · 261 citations

, , +16

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

Anwesha Chaudhury, Nadia Solovieff, Laia Paré et al. · Journal of Clinical Oncology · 2021 · 153 citations · Full text

, , +17